This phase III trial compares a smartphone application with or without nicotine replacement therapy in improving smoking cessation among Hispanic adults who would like to quit smoking. The iCanQuit smartphone application focuses on skills for managing urges, motivation, and relapse prevention with personalized quit plans. Nicotine replacement therapy works by giving small, steady doses of nicotine to help stop cravings and relieve symptoms that occur when a person is trying to quit smoking without any of the other harmful chemicals found in tobacco products.

Start Date01 Nov 2025

Sponsor / Collaborator

Fred Hutchinson Cancer Research Center

[+1]

NCT07089901

/ Not yet recruitingPhase 4IIT

Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment

Tobacco use is a chronic relapsing condition. That is, even with state-of-the-art treatment, >70% of smoking cessation attempts end in a return to regular smoking. Research demonstrates that everyday environments associated with smoking trigger craving for cigarettes, provoke smoking, and lead to relapse. However, despite this knowledge, understanding of environmental correlates of smoking has been limited by a reliance on self-report, leading to imprecise information about the physical environments in which people live. To overcome this challenge, the research team has pioneered the development of digital envirotyping, which uses digital tools (e.g., sensors, cameras, artificial intelligence) to efficiently and accurately characterize and categorize environments with the goal of identifying environmental markers of behavior and health. Foundational to the digital envirotyping research is computer vision (CV), a type of artificial intelligence (AI) that enables computer systems to recognize objects and scenes in digital images, mimicking how humans perceive and understand visual information. With CV researchers can extract detailed and accurate information (i.e., objects and location types) about the everyday environments of people who smoke (PWS) and relate that information to smoking behavior. After validating the use of CV, the researchers used CV to develop enviromarkers of relapse risk. Importantly, they identified a novel enviromarker in which people at greater risk for relapse when they quit are exposed to a more consistent level of environment-related smoking risk as they move between their smoking and nonsmoking environments.
Research is now needed to advance digital envirotyping and enviromarker development in the field of tobacco addiction. The study will recruit a diverse, national sample of n=500 adults who are interested in quitting smoking. For two weeks prior to quitting, they will undergo photoEMA in which they will take two pictures of their current environment when they smoke, and randomly 10 times per day resulting in >300,000 images total. Cessation will be supported by nicotine replacement therapy (i.e., nicotine patch). The primary clinical outcome will be days to relapse. Specific aims are to (1) further develop, refine, and validate methods for efficient digital envirotyping at scale, (2) leverage CV and AI approaches to develop enviromarkers of smoking relapse, and (3) conduct analyses to increase understanding of environmental smoking risk in women and individuals with low socioeconomic status.

Start Date01 Nov 2025

Sponsor / Collaborator

Duke University

[+1]

NCT07099638

/ Not yet recruitingPhase 2IIT

Randomized Factorial Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention to Promote Smoking Cessation

Although the prevalence of smoking has declined among U.S. adults, smoking remains the leading preventable cause of cancer incidence and mortality. Quitting smoking increases life expectancy, and quitting at an earlier age is associated with more years of life gained. Effective pharmacotherapies to aid cessation are available, and the combination of behavioral support with pharmacotherapy optimizes cessation outcomes. Varenicline is an effective, first-line smoking cessation treatment, and recent research has investigated combination pharmacotherapy to improve the modest quit rates observed with monotherapy. The findings of two meta-analyses have indicated that varenicline combined with the nicotine patch was more effective than varenicline alone for smoking cessation However, no published studies to date have evaluated the combined impact of varenicline and oral nicotine replacement therapy (NRT) on smoking cessation in a randomized trial. Oral NRT, such as nicotine lozenges, can provide acute relief from cravings/withdrawal, and offers individuals the flexibility to deliver nicotine quickly, in contrast with the continuous, passive, and slow-acting delivery of the nicotine patch. Nevertheless, in clinical trials of other combination pharmacotherapies, participants' adherence to of oral NRT has been suboptimal, making it difficult to determine whether there is an added benefit. Given the near-ubiquity of smartphone ownership (85% of U.S. adults), it is plausible that smartphone-based medication adherence interventions could have a positive influence on pharmacotherapy adherence and smoking cessation. This investigative team has demonstrated the feasibility and potential efficacy of using combination varenicline plus oral NRT treatment to promote smoking cessation in a pilot factorial randomized trial. Likewise, pilot findings showed that medication adherence and smoking cessation rates were higher among those who received smartphone-based medication reminders than those who did not. The proposed study will enroll 496 adults who smoke cigarettes daily. The study will employ a 2x2 factorial design in which participants will be randomized to one of four combinations of two treatment factors: 1) pharmacological treatment (varenicline + nicotine lozenges vs. varenicline alone) and 2) smartphone medication adherence intervention (smartphone-based smoking cessation app with vs. without adherence components). The primary study outcomes will be biochemically-confirmed 7-day point prevalence abstinence at 26 weeks after a scheduled quit date, and medication adherence over the 13-week treatment period. Smartphone-based daily diaries will be employed to assess daily smoking and medication adherence. Notably, the proposed study will employ entirely remote assessment and treatment delivery strategies. Exploratory analyses will evaluate the potential interaction between medication type and the smartphone adherence intervention, and compare the influences of pharmacological treatment type and the medication adherence intervention on weekly physical symptoms (e.g., withdrawal, medication side effects). The overarching goal of the proposed research is to improve smoking cessation treatment and decrease cancer risk.

Start Date01 Oct 2025

Sponsor / Collaborator

University of Oklahoma

[+5]

100 Clinical Results associated with Nicotine

100 Translational Medicine associated with Nicotine

100 Patents (Medical) associated with Nicotine

40,091

Literatures (Medical) associated with Nicotine

31 Dec 2025·AUSTRALIAN JOURNAL OF PSYCHOLOGY

The relationship between work addiction and addictions to social media, shopping, food, caffeine, and nicotine

Article

Author: Onay, Ömer Alperen ; Griffiths, Mark D. ; Tınmaz Karaçay, Gülay ; Özsoy, Emrah ; Yılmaz, Canan ; Balaban, Özlem

Purpose:

Work addiction is a relatively underexplored behaviour compared to other forms of addiction. Existing research predominantly focuses on the antecedents and consequences of work addiction. However, studies examining its relationship with other types of addiction are notably limited. Therefore the present study investigated the relationships between work addiction and five other types of addiction (i.e. social media addiction, shopping addiction, food addiction, caffeine addiction, and nicotine addiction).

Method:

The research was conducted with 693 employees working in both public and private sectors. Data were collected through an online survey comprising validated scales for assessing the specific types of addiction and demographic questions. Descriptive statistics, internal consistency tests and Pearson correlation analysis were employed for data analysis.

Results:

Correlation analysis showed significant (albeit weak) positive relationships between work addiction and food addiction (r = .14), shopping addiction (r = .12), and caffeine addiction (r = .16). However, no significant relationships were found between work addiction and social media addiction or nicotine addiction. Comorbidity among individuals classified as high-risk for more than one addiction was only observed between two substance-based addictions (caffeine and nicotine), and between one substance-based addiction (caffeine) and one behavioural addiction (social media).

Conclusions:

These findings suggest that although multiple behavioural addictions may be associated, the observed comorbidity patterns primarily occur between two substance-based addictions or between a substance-based and a behavioural addiction, rather than between two behavioural addictions.

01 Dec 2025·IBRO Neuroscience Reports

Evaluation of the role of omega-3 fatty acids in nicotine-induced neurotoxicity in pregnant Wistar rats and their pups

Article

Author: Aturamu, Ayodeji ; Samuel, Tokunbo Olorunfemi ; Elemile, Mayowa Grace ; Omotosho, Gbenga Olatunde ; Alabi, Quadri Kunle ; Ibiye, Orji Eunice ; Ayoka, Oladele Abiodun ; Ige, Samson Mokolade ; Olamilosoye, Peace Kehinde ; Omole, Joseph Gbenga ; Adefisayo, Modinat Adebukola ; Ogunleye, Fisayo Nathaniel

This study investigated maternal and their pup neurobehaviour following nicotine exposure during gestational and postnatal periods and neuroprotective effect of Omega-3 fatty acids. Thus, the study used thirty pregnant female Wistar rats for this study. Groups I and II (nonpregnant and pregnant) were treated with 1 ml/kg/day of normal saline for 42 days; III was treated with 4 mg/kg/day of nicotine for 42 days; IV-VI were co-administered nicotine 4 mg/kg and 100, 300, 600 mg/kg/day of Omega-3 fatty acids respectively for 42 days. Results: The beam walk time of the mother rats in groups III and IV were significantly higher when compared with other groups. Similarly, the beam walks time of the pups of groups III and IV were significantly higher when compared with the pups of the mother rats in other groups. The brain dopamine and serotonin levels of mother rats in groups III, IV and V were significantly higher when compared with other groups. Also, the brain dopamine and serotonin levels of the pups in groups III and IV were significantly higher when compared with the pups in other groups. The reduced glutathione and catalase of mother and pup rats in groups III and IV were significantly lower when compared with other groups. Photomicrographs of cerebellum and hippocampus of the rats treated with nicotine showed scattered arrangement of pyramidal cells with vacuolated neurons. These alterations were significantly reversed with Omega-3 fatty acids following nicotine exposure. Conclusions. Omega-3 fatty acids at 300 and 600 mg/kg ameliorated nicotine-induced neurotoxicity in mother rats and their pups.

01 Dec 2025·Toxicology reports

Analysing the acute toxicity of e-cigarette liquids and their vapour on human lung epithelial (A549) cells in vitro

Article

Author: Donnellan, Samantha ; Findlay-Greene, Fern ; Vass, Sharron

The use of alternative tobacco products such as vaping devices has significantly increased over the last 5-years, with the largest increase being amongst 18-25-year-olds. While the quantity of nicotine is tightly regulated, the composition of e-liquid flavourings is largely unregulated, and often absent from product labels. Herein, we compare the toxicity of carrier liquids propylene glycol (PG) & vegetable glycerine (VG) with five popular flavour concentrates: menthol, cherry, butterscotch, vanilla bourbon and tobacco on human alveolar type II cell-like A549 cells. The flavourings were tested in both liquid and vapour form and a vapour assay was developed to assess cytotoxicity of the flavourings. Our results conclude that menthol liquid was the most cytotoxic (LD₅₀ = <0.5 % over a <4 h exposure). Followed by cherry and vanilla bourbon which elicited a similar response at 4 % over 8 h exposure. Tobacco only reached 50 % toxicity at a concentration > 4 % over 24 h exposure. Butterscotch displayed similar toxicity profiles to PG and VG where cytotoxicity exceeded 20 % at 8 % concentration at all time points. The cytotoxicity of menthol was further evaluated as a vapour, with a significant reduction in viable cells and a 5-fold increase in the number of necrotic cells with only 11 % of cells remaining viable after 5 vaping episodes. Analysis revealed the presence of toxic chemicals and heavy metals in the fluids therefore further research is required to fully elucidate the long-term usage of flavourings with vaping devices and the impact this may have on human lung health.

196

News (Medical) associated with Nicotine

21 Aug 2025

·www.prnewswire.com

Northern Colorado's only fully integrated, state-licensed center unites psychiatry and psychedelic therapy under one roof

FORT COLLINS, Colo., Aug. 21, 2025 /PRNewswire/ -- The Wholeness Center has received state approval to launch legal psilocybin-assisted therapy, becoming Northern Colorado's only licensed healing center and the state's first clinic where psychedelic services and integrative psychiatry operate under one roof. Continue Reading A New Era of Mental Health Care The new license allows Wholeness to combine its renowned expertise in psychiatry, naturopathic medicine, and integrative medicine with guided psilocybin sessions led by licensed clinical facilitators. This creates an end-to-end continuum of care for conditions such as depression, anxiety, trauma, and substance misuse. Clients undergo a comprehensive medical and psychological assessment, individualized preparation, expert-supported dosing, and multi-disciplinary integration to translate insights into lasting change. The Wholeness Center has received state approval to launch legal psilocybin-assisted therapy. Post this "Our co-located model means clients never have to choose between cutting-edge psychedelic care and trusted medical support. Everything is here, working together for whole-person healing," says Dr. Scott Shannon, co-founder and psychiatrist. Deep Roots in Psychedelic Research Dr. Scott Shannon and the Wholeness Center have been instrumental in advancing psychedelic medicine by integrating a holistic, spiritually informed clinical framework with rigorous scientific practice. Through pioneering partnerships, including serving as a principal investigator in MAPS's MDMA-assisted psychotherapy trials and conducting multi-site MindMed-sponsored LSD and psilocybin studies, the center has helped set best-practice standards for trial design, set and setting protocols, and interdisciplinary care. Wholeness is a leader in bringing forward new, evidence-based treatments for some of the most challenging mental health conditions. Key Psilocybin-Assisted Therapy Findings from Clinical Research Clinical trials at Johns Hopkins Medicine found that two psilocybin doses with psychotherapy produced large, rapid reductions in depression symptoms. Nearly half of participants achieved remission within four weeks, with benefits lasting up to a year. In long-term follow-up, 67% of participants remained in remission five years later, an unprecedented duration of therapeutic effect. An open-label pilot study published in the Journal of Affective Disorders reported that a single 25 mg dose of psilocybin led to a 60% response rate and a 53% remission rate of Treatment-Resistant Depression in U.S. military veterans within three weeks, with nearly half maintaining benefits at twelve weeks. Participants in clinical trials also reported greater life satisfaction, spiritual well-being, and improvements in overall health, benefits that extend well beyond symptom relief. Additionally, early clinical evidence indicates psilocybin may help address suicidality, anxiety disorders, obsessive-compulsive disorder, and addictions to alcohol, opiates and nicotine, often showing superior outcomes and low toxicity compared to standard treatments. Learn More or Get Started Patients, providers, and media can learn more or schedule an exploratory call by visiting the Wholeness Center website or contacting [email protected]. Limited openings available now, refer or call today to reserve a spot. Sources: Frontiers in Psychiatry, JAMA, JAMA Psychiatry, Psychiatry Research, U.S. Food and Drug Administration, National Center for Complementary and Integrative Health SOURCE The Wholeness Center WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Study

08 Aug 2025

·pharma.economictimes.indiatimes.com

Zydus’ anti-smoking drug secures approval in Canada

Ahmedabad: Zydus Lifesciences announced that its anti-smoking generic drug ‘ ZDS-Varenicline ’ has secured regulatory approval in Canada. marketing has received marketing approval The company has received Notice of Compliance (NOC) the country’s nodal drug regulator Health Canada and Varenicline is a popular partial nicotinic acetylcholine receptor agonist, used as an aid in smoking cessation . The drug is designed to partially activate the nicotinic acetylcholine receptor (nAChR, while displacing nicotine at its sites of action in the brain. Unlike nicotine replacement therapies, such as patches, gums etc., these drugs do not contain nicotine, but targets the nicotinic acetylcholine receptors which helps to reduce nicotine cravings and withdrawal symptoms. According to IQVIA, in 2024 the drug reported total sales of ‘15 million Canadian dollar’ (around ₹94 crore). As per the company release, this is the group’s first NOC approval in Canada and the drug will be manufactured at its Ahmedabad plant in India. By Online Bureau ,

Drug Approval

16 Jun 2025

·www.einpresswire.com

Dr. Bernard Fialkoff presents Scientific Findings Regarding Vaping, Marijuana, Opioid Gateways to Addiction / Dependency

Dr. Bernard Fialkoff presents Scientific Findings Regarding Vaping, Marijuana, Opioid Gateways to Albany Dentists on Predisposition to Addiction / Dependency Nicotine, found in most e-cigarettes, is an addictive drug that can negatively impact brain development in young people.” — Surgeon General Dr. Vivek Murthy MD ALBANY, NY, UNITED STATES, June 16, 2025 / EINPresswire.com / -- Should Health Professionals Educate to Foster Drug Free Living and Increased Wellness Amongst Patients ? In 2025, we face a global crisis of drug and illicit substance abuse undermining family structure and the Sustainable Development Goals of the United Nations. National cultures and our own local communities are under attack from fentanyl, synthetic drugs, and illicit substances, which caused ~ 113,000 deaths in the United States in 2023 - CDC. This surpassed the 58,000 American deaths during 10 years of Vietnam War - World Report. The 2021 UNODC World Drug Report stated that drug abuse affected an alarming 275 million people worldwide in 2021, with more than 36 million people suffering from drug-related disorders. The drug crisis continues to erode the future of society - essential family structure and the dreams of our children. Some disturbing scientific facts have emerged demonstrating that vape heating element metals are toxic with lead, tin, arsenic, nickel - Rule PhD John Hopkins; That approximately 99% of vaping flavorings contain nicotine - CDC; And nicotine adversely affects the developing brain from 13 to 25 years of age - CDC; That vaping leads to a 50 % increase in marijuana usage - New England Journal of Medicine; And marijuana use leads to opioid misuse disorder - Psychopharmacology / American Journal of Psychiatry; And finally that marijuana use by pregnant mothers leads to newborn neurosis and psychosis - JAMA. On November 20, 1989, the United Nations General Assembly adopted the Convention on the Rights of the Child. Article 3-1 states: “In all actions concerning children, whether undertaken by public or private social welfare institutions, courts of law, administrative authorities, or legislative bodies, the best interests of the child shall be a primary consideration.” Article 33 adds: “States Parties shall take all appropriate measures, including legislative, administrative, social, and educational measures, to protect children from the illicit use of narcotic drugs and psychotropic substances.” The 2016 UNGASS World Drug Conference concluded that education and prevention are important keys to managing the global drug epidemic. It is important to note that if parents talk to their children about drugs, there is a 40% lower chance that those children will use them. If we educate children early and delay substance use until after age 21, statistics show there is less risk of addiction - SAMSHA According to the NIH and many scientific journals—timely education can guide young people toward informed, healthy decisions. Let us not be deceived into thinking that our responsibility ends within the 4 walls of our offices. There is no demographic exclusion when it comes to drug addiction; no one is exempt. Community wellness depends on the scientific guiding efforts of health professionals. The American Dental Association recenly published that nearly 70 % of patients are comfortable talking to their dentist about marijuana. Dr. Vivek Murthy, U.S. Surgeon General, stated: “Loneliness is much more than a simple negative feeling: it harms both individual and social health.” It is associated with higher risks of cardiovascular disease, dementia, stroke, depression, anxiety, and premature death. The mortality impact of social disconnection is comparable to smoking up to 15 cigarettes a day, and greater than that caused by obesity or physical inactivity. The consequences of a society lacking social connection can be felt in our homes, workplaces, and civic organizations—where productivity and commitment decrease. Given the profound consequences of loneliness and isolation, we have a responsibility and an obligation to invest just as much in addressing social connection as we do in combating tobacco use, obesity, and the addiction crisis. This Surgeon General’s Advisory shows us how to build a more connected world. If we fail to do so, we will pay an increasing price in terms of health and individual and collective well-being. We will continue to fragment and divide ourselves—leaving us isolated, angry, and alone. Gandhi said: “Be the change you wish to see in the world.” Martin Luther King said: “Our lives begin to end the day we become silent about things that matter.” George Washington said: “One of the primary goals must be the education of our youth. What greater task than to communicate with those who will be the future guardians of the country’s freedoms ? " Health practitioners are natural counselors and trusted professionals. Health provider scientifically based education can mitigate the addiction and dependency of our patients and communities. The Health Professions can lead in this war against illicit drugs by setting a good example in protecting community wellness, and as the Surgeon General has asked for by increasing social connection and responsibility.. Dr. Bernard Fialkoff 44 Year Periodontal and Implant Surgeon Bernardfialkoffdds@gmail.com Dr. Bernard Fialkoff DDS Dr. Bernard Fialkoff DDS +1 516-647-2126 bernardfialkoffdds@gmail.com Visit us on social media: Instagram Facebook YouTube The Science of Vaping and Marijuana Gateways Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Nicotine

External Link

KEGG	Wiki	ATC	Drug Bank
D03365	Nicotine	N07BA01	DB00184

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Tobacco Use Disorder	Australia	Johnson & Johnson Pacific Pty Ltd.	27 Nov 2001
Nicotine Dependence	United States	Haleon US Capital LLC	13 Jan 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acral Lentiginous Malignant Melanoma	Phase 3	United States	McNeil AB	01 Mar 2011
Smoking Cessation	Phase 3	Czechia	McNeil AB	01 Feb 1999
Dyskinesia, Drug-Induced	Phase 2	United States	Neuraltus Pharmaceuticals, Inc.	01 Oct 2009
Parkinson Disease	Phase 2	United States	Neuraltus Pharmaceuticals, Inc.	01 Oct 2009
Lung Cancer	Phase 1	United States	Pfizer Inc.	16 Jun 2017
disorder of aging	Preclinical	China	The Shenzhen Institutes of Advanced Technology	07 Feb 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04590404 (CTgov)	Phase 3	Smoking	606	Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)+Nicotine Replacement Therapy+Varenicline	klypwtscrl = rqdaqlfhsb oolauyifms (nibcwbxzec, bsawmqahmm - rnqgsrehjr) View more	-	05 Jun 2025
NCT05030766 (CTgov)	Phase 4	Smoking Cessation \| HIV Infections \| Smoking	95	Nicotine replacement patches (Mindfulness Training (MT) and NRT (Phase 1))	ozyekfzpls = lecwnfawfr mvqxvzdijn (mzzpmcjpho, ulptmhkqql - othlajssyw) View more	-	04 Jun 2025
				Nicotine replacement patches+NRT (Contingency Management (CM) and NRT (Phase 1))	ozyekfzpls = yvjijqmrju mvqxvzdijn (mzzpmcjpho, ljzeqsmjkn - cxseckntgq) View more
NCT04946825 (CTgov)	Phase 2	Smoking Cessation \| Nicotine Dependence	396	Nicotine replacement therapy patch+Continue electronic cigarettes (Quit Cigarettes, But Continue Using E-cigarettes, With Nicotine Replacement Therapy and Text Support)	cfcucsqcvq = gzkunuctri axjlhcnpxy (lqarcfsjvi, kyguyqdyja - knzaidpzqx) View more	-	22 May 2025
				Nicotine replacement therapy patch+Quit electronic cigarettes (Quit Cigarettes and Quit E-cigarettes With Nicotine Replacement Therapy and Text Support.)	cfcucsqcvq = tdirsobqyl axjlhcnpxy (lqarcfsjvi, wytpxtvdyl - zygjccgvxh) View more
NCT02265874 (CTgov)	Phase 1/2	Sarcoidosis, Pulmonary	50	Habitrol (Treatment)	khyhftbfuy(ynrptihtal) = xpbihkdmpv vvdcumfqyf (vgudeyhepx, 0.22) View more	-	24 Apr 2025
				Placebo to Habitrol (Control)	khyhftbfuy(ynrptihtal) = beatrgwqbq vvdcumfqyf (vgudeyhepx, 0.04) View more
NCT04994444 (CTgov)	Phase 2/3	Smoking Cessation	49	Nicoderm CQ (Preloading)	wacqkelilb(tayoigaawg) = ttdcafzehn yvgprgvyil (mlndjpqobj, 13.2) View more	-	06 Apr 2025
				Nicoderm CQ (Standard Treatment)	wacqkelilb(tayoigaawg) = xccjhytvfk yvgprgvyil (mlndjpqobj, 21.8) View more
NCT04433767 (Pubmed)	Phase 2	Depressive Disorder nicotine metabolite concentrations	29	Transdermal nicotine patches	zunusfqnwo(xuiphjtyax) = improvement in self-reported affective symptoms (apathy, insomnia, rumination, and generalized anxiety symptoms), negativity bias, and disability xvyxepvhwx (yjqatyesib ) View more	Positive	01 Oct 2024
NCT05253573 (SurvLaos, CTgov)	Phase 2	Neoplasms \| Smoking	80	Self-help materials (to support smoking cessation)+Nicotine patch (Automated Treatment)	hcoplasmst = sjkfpyiblp yjkdhdhtox (loxeyhziyj, wbyorvfuju - tszhifqsao) View more	-	28 Aug 2024
				Self-help materials (to support smoking cessation)+Nicotine patch (Standard Care)	hcoplasmst = qguqqxqzbb yjkdhdhtox (loxeyhziyj, viqobichjf - jntdrpwzxt) View more
NCT03612960 (CTgov)	Not Applicable	Acral Lentiginous Malignant Melanoma	34	Very low nicotine content cigarettes (Very Low Nicotine Content Cigarettes)	onadwbyeot(avlxcvcjpf) = pebpzrmitu uzaecryosm (mjfzkpgevw, 0.18) View more	-	20 Aug 2024
				Normal nicotine content cigarettes (Normal Nicotine Content Cigarettes)	onadwbyeot(avlxcvcjpf) = wlwqjecywd uzaecryosm (mjfzkpgevw, 0.18) View more
NCT03272685 (CTgov)	Phase 3	Nicotine Dependence	799	Very Low Nicotine Content Cigarettes (Very Low Nicotine Content Cigarettes)	rbxtishkqm(phdwgjyylx) = azflrpuqtb hwobzhegyy (gntpwxmtlg, 7.88) View more	-	20 Aug 2024
				Normal Nicotine Content Cigarettes (Normal Nicotine Content Cigarettes)	rbxtishkqm(phdwgjyylx) = ahtizhpxnn hwobzhegyy (gntpwxmtlg, 9.07) View more
NCT03634839 (CTgov)	Phase 1	Tobacco Use Disorder	42	Flavoring Agents+Nicotine (Sweet Non-menthol, Nicotine 36mg/ml)	yokmnrrnqm(ozaprhykfx) = flrcorvptg sjfxswrwvu (nradcossvr, 3.158) View more	-	09 Aug 2024
				Flavoring Agents+Nicotine (Sweet Menthol, Nicotine 36mg/ml)	yokmnrrnqm(ozaprhykfx) = oqwfekngur sjfxswrwvu (nradcossvr, 3.158) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis